• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is REVTORPYK’s First‑in‑Class FDA Approval Reframing the Investment Case For Celcuity (CELC)?

    Simply Wall St·07/31/2026 04:40:08
    语音播报
    • In July 2026, Celcuity announced that its drug REVTORPYK (gedatolisib) received FDA approval and NCCN Category 1 preferred guideline status for use with fulvestrant, with or without palbociclib, in adults with HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation after progression on endocrine therapy.
    • A key differentiator is that REVTORPYK is the only FDA-approved therapy targeting all class I PI3K isoforms and both mTORC1 and mTORC2 complexes, supported by VIKTORIA-1 trial data showing a very large improvement in median progression-free survival versus fulvestrant alone in the PIK3CA wild-type population.
    • We’ll now examine how REVTORPYK’s FDA approval and NCCN Category 1 preferred status could reshape Celcuity’s previously pre-commercial investment narrative.

    AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    Celcuity Investment Narrative Recap

    To own Celcuity today, you have to believe REVTORPYK’s first approval can transition the company from a cash burning, pre commercial story into one anchored by real product uptake. The FDA approval and NCCN Category 1 preferred status appear to resolve near term regulatory uncertainty, shifting the key catalyst toward the early commercial launch trajectory, while the biggest near term risk now centers on whether payer access, physician adoption and safety management support meaningful use in routine practice.

    Against that backdrop, Celcuity’s June 2026 upsized US$500,000,000 convertible note offering matters because it largely pre funded this launch phase and broader development plans. Prior to approval, the company was carrying substantial operating losses and had already built out a commercial infrastructure, so this added capital provides runway but also heightens execution risk if REVTORPYK uptake or future indications do not support the larger balance sheet and cost base.

    However, investors should also be aware that if payer access, physician adoption or safety perceptions lag expectations, the combination of high fixed costs and new debt could...

    Read the full narrative on Celcuity (it's free!)

    Celcuity's narrative projects $817.9 million revenue and $267.5 million earnings by 2029. This implies an earnings increase of about $460 million from -$192.9 million today.

    Uncover how Celcuity's forecasts yield a $161.09 fair value, a 84% upside to its current price.

    Exploring Other Perspectives

    CELC 1-Year Stock Price Chart
    CELC 1-Year Stock Price Chart

    Before this approval, the most optimistic analysts were already modeling about US$1.4 billion of revenue and US$562.1 million of earnings by 2029, so compared with consensus they were embracing a far more ambitious catalyst path that could either be supported or challenged as the real world REVTORPYK launch, label usage and cost base outcomes become clearer.

    Explore 4 other fair value estimates on Celcuity - why the stock might be worth just $161.09!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Searching For A Fresh Perspective?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.